1. Home
  2. AVDL

AVDL

Avadel Pharmaceuticals plc

Logo Avadel Pharmaceuticals plc

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-19-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. It identifies, develops, and commercializes branded pharmaceutical products including controlled-release therapeutic products based on its proprietary drug delivery technologies in the United States. The company is engaged in development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy.

Founded: N/A Country:
Ireland
Ireland
Employees: N/A City: DUBLIN
Market Cap: 1.6B IPO Year: 1996
Target Price: $23.00 AVG Volume (30 days): 1.2M
Analyst Decision: Strong Buy Number of Analysts: 8
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.00 EPS Growth: N/A
52 Week Low/High: $9.50 - $17.47 Next Earning Date: 05-02-2024
Revenue: $27,963,000 Revenue Growth: N/A
Revenue Growth (this year): 491.57% Revenue Growth (next year): 79.99%

Share on Social Networks: